Caris Life Sciences (NASDAQ:CAI) Shares Gap Up After Better-Than-Expected Earnings

Caris Life Sciences, Inc. (NASDAQ:CAI) gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $19.24, but opened at $21.16. Caris Life Sciences shares last traded at $21.32, with a volume of 1,119,366 shares.

The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.01 by $0.27. The company had revenue of $292.89 million for the quarter, compared to the consensus estimate of $281.00 million. The firm’s revenue for the quarter was up 125.4% compared to the same quarter last year. During the same period last year, the company posted ($1.73) earnings per share.

Key Headlines Impacting Caris Life Sciences

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 beat and strong revenue growth — CAI reported GAAP EPS of $0.28 (well above estimates) and Q4 revenue of ~$293M, up ~125% YoY, demonstrating accelerating top‑line momentum. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Major interim Achieve 1 readout — The company announced interim data showing Caris Detect (WGS + AI) had superior sensitivity and specificity vs. methylation‑based approaches, a milestone for its MCED launch and long‑term growth potential in early cancer detection. Caris Life Sciences Completes Interim Readout of Achieve 1 Study
• Positive Sentiment: 2026 revenue guidance reaffirmed/raised — Management guided full‑year 2026 revenue to roughly $1.0B–$1.02B (above consensus), supporting sustained growth expectations as profiling services and new product launches scale. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Analyst support — Robert W. Baird initiated coverage / raised its price target (to $28 with an Outperform stance), bringing new institutional attention that can boost demand for the stock. Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
• Positive Sentiment: Product enhancement — Caris added an AI‑powered breast cancer signature to its Caris Molecular Tumor Board Report, expanding clinical utility and potential revenue per case in precision oncology. Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report
• Neutral Sentiment: Mixed analyst moves — BTIG lowered its price target from $45 to $38 but maintained a Buy rating; still bullish but the cut tempers some upside expectations. BTIG price target note
• Neutral Sentiment: Further reading / call details — The Q4 earnings call transcript and additional materials are available for investors who want management commentary on Caris Detect commercialization timing and margin cadence. Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call Transcript

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Evercore set a $38.00 target price on Caris Life Sciences in a research note on Monday, January 5th. Wall Street Zen cut shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. BTIG Research reduced their target price on shares of Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Finally, Canaccord Genuity Group lifted their price target on Caris Life Sciences from $28.00 to $30.00 and gave the company a “hold” rating in a report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Caris Life Sciences has a consensus rating of “Hold” and an average price target of $33.50.

Insider Buying and Selling

In other Caris Life Sciences news, insider Luke Thomas Power sold 62,250 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the sale, the insider directly owned 99,571 shares in the company, valued at approximately $2,646,597.18. The trade was a 38.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 7.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. raised its holdings in Caris Life Sciences by 14.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock worth $248,377,000 after purchasing an additional 1,180,200 shares in the last quarter. Braidwell LP increased its position in shares of Caris Life Sciences by 6.8% during the 4th quarter. Braidwell LP now owns 7,816,142 shares of the company’s stock valued at $210,880,000 after purchasing an additional 500,000 shares during the period. PointState Capital LP raised its stake in shares of Caris Life Sciences by 73.0% in the 4th quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock worth $181,271,000 after buying an additional 2,834,986 shares in the last quarter. Orbimed Advisors LLC lifted its holdings in shares of Caris Life Sciences by 2.7% in the fourth quarter. Orbimed Advisors LLC now owns 3,116,011 shares of the company’s stock valued at $84,070,000 after buying an additional 81,153 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Caris Life Sciences by 185.0% during the fourth quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock valued at $65,974,000 after buying an additional 1,587,176 shares in the last quarter.

Caris Life Sciences Price Performance

The company has a debt-to-equity ratio of 0.79, a current ratio of 9.93 and a quick ratio of 9.36. The stock has a fifty day moving average price of $24.42. The stock has a market capitalization of $5.68 billion and a PE ratio of -43.78.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.